These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38941892)

  • 1. Xelaglifam, a novel GPR40/FFAR1 agonist, exhibits enhanced β-arrestin recruitment and sustained glycemic control for type 2 diabetes.
    Yoon J; Lee DG; Song H; Hong D; Park JS; Hong C; An KM; Lee JW; Park JT; Yoon H; Tak J; Kim SG
    Biomed Pharmacother; 2024 Aug; 177():117044. PubMed ID: 38941892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.
    Bazydlo-Guzenda K; Buda P; Matloka M; Mach M; Stelmach F; Dzida R; Smuga D; Hucz-Kalitowska J; Teska-Kaminska M; Vialichka V; Dubiel K; Kaminska B; Wieczorek M; Pieczykolan J
    Mol Pharmacol; 2021 Oct; 100(4):335-347. PubMed ID: 34349026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
    Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
    J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF rats.
    Gowda N; Dandu A; Singh J; Biswas S; Raghav V; Lakshmi MN; Shilpa PC; Sunil V; Reddy A; Sadasivuni M; Aparna K; Verma MK; Moolemath Y; Anup MO; Venkataranganna MV; Somesh BP; Jagannath MR
    BMC Pharmacol Toxicol; 2013 May; 14():28. PubMed ID: 23692921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Exposure to SCO-267, an Allosteric GPR40 Full Agonist, Is Effective in Improving Glycemic Control in Rats.
    Koyama R; Ookawara M; Watanabe M; Moritoh Y
    Mol Pharmacol; 2021 Apr; 99(4):286-293. PubMed ID: 33547250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity.
    Ueno H; Ito R; Abe SI; Ookawara M; Miyashita H; Ogino H; Miyamoto Y; Yoshihara T; Kobayashi A; Tsujihata Y; Takeuchi K; Watanabe M; Yamada Y; Maekawa T; Nishigaki N; Moritoh Y
    J Pharmacol Exp Ther; 2019 Aug; 370(2):172-181. PubMed ID: 31182471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-Arrestin Recruitment and Biased Agonism at Free Fatty Acid Receptor 1.
    Mancini AD; Bertrand G; Vivot K; Carpentier É; Tremblay C; Ghislain J; Bouvier M; Poitout V
    J Biol Chem; 2015 Aug; 290(34):21131-21140. PubMed ID: 26157145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats.
    Matsumoto K; Yoshitomi T; Ishimoto Y; Tanaka N; Takahashi K; Watanabe A; Chiba K
    J Pharmacol Exp Ther; 2018 Dec; 367(3):509-517. PubMed ID: 30217957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats.
    Ito R; Tsujihata Y; Matsuda-Nagasumi K; Mori I; Negoro N; Takeuchi K
    Br J Pharmacol; 2013 Oct; 170(3):568-80. PubMed ID: 23848179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients.
    Sunil V; Verma MK; Oommen AM; Sadasivuni M; Singh J; Vijayraghav DN; Chandravanshi B; Shetty J; Biswas S; Dandu A; Moolemath Y; Venkataranganna MV; Somesh BP; Jagannath MR
    BMC Pharmacol Toxicol; 2014 Mar; 15():19. PubMed ID: 24666736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
    Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
    Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1.
    Yabuki C; Komatsu H; Tsujihata Y; Maeda R; Ito R; Matsuda-Nagasumi K; Sakuma K; Miyawaki K; Kikuchi N; Takeuchi K; Habata Y; Mori M
    PLoS One; 2013; 8(10):e76280. PubMed ID: 24130766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
    Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
    Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve.
    Ueno H; Ito R; Abe SI; Ogino H; Maruyama M; Miyashita H; Miyamoto Y; Moritoh Y; Tsujihata Y; Takeuchi K; Nishigaki N
    PLoS One; 2019; 14(9):e0222653. PubMed ID: 31525244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, molecular docking, dynamic simulation and pharmacological characterization of potent multifunctional agent (dual GPR40-PPARγ agonist) for the treatment of experimental type 2 diabetes.
    Hidalgo-Figueroa S; Rodríguez-Luévano A; Almanza-Pérez JC; Giacoman-Martínez A; Ortiz-Andrade R; León-Rivera I; Navarrete-Vázquez G
    Eur J Pharmacol; 2021 Sep; 907():174244. PubMed ID: 34116041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fasiglifam/TAK-875, a Selective GPR40 Agonist, Improves Hyperglycemia in Rats Unresponsive to Sulfonylureas and Acts Additively with Sulfonylureas.
    Ito R; Tsujihata Y; Suzuki M; Miyawaki K; Matsuda K; Takeuchi K
    J Pharmacol Exp Ther; 2016 Apr; 357(1):217-27. PubMed ID: 26813930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yhhu4488, a novel GPR40 agonist, promotes GLP-1 secretion and exerts anti-diabetic effect in rodent models.
    Guo DY; Li DW; Ning MM; Dang XY; Zhang LN; Zeng LM; Hu YH; Leng Y
    Biochem Biophys Res Commun; 2015 Oct; 466(4):740-7. PubMed ID: 26417688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute administration of GPR40 receptor agonist potentiates glucose-stimulated insulin secretion in vivo in the rat.
    Doshi LS; Brahma MK; Sayyed SG; Dixit AV; Chandak PG; Pamidiboina V; Motiwala HF; Sharma SD; Nemmani KV
    Metabolism; 2009 Mar; 58(3):333-43. PubMed ID: 19217448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GPR40 partial agonist MK-2305 lower fasting glucose in the Goto Kakizaki rat via suppression of endogenous glucose production.
    Miller C; Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Bunzel M; Cao J; Souza S; Thomas-Fowlkes B; Di Salvo J; Weinglass AB; Li X; Myers RW; Knagge K; Carrington PE; Hagmann WK; Trujillo ME
    PLoS One; 2017; 12(5):e0176182. PubMed ID: 28542610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents.
    Lin DC; Zhang J; Zhuang R; Li F; Nguyen K; Chen M; Tran T; Lopez E; Lu JY; Li XN; Tang L; Tonn GR; Swaminath G; Reagan JD; Chen JL; Tian H; Lin YJ; Houze JB; Luo J
    PLoS One; 2011; 6(11):e27270. PubMed ID: 22087278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.